Share on StockTwits

Genocea Biosciences (NASDAQ:GNCA) major shareholder Polaris Venture Management Co. sold 9,660 shares of Genocea Biosciences stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $13.01, for a total value of $125,676.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Shares of Genocea Biosciences (NASDAQ:GNCA) traded up 2.08% during mid-day trading on Friday, hitting $13.23. 10,872 shares of the company’s stock traded hands. Genocea Biosciences has a 52-week low of $10.90 and a 52-week high of $23.99. The stock’s 50-day moving average is $15.69 and its 200-day moving average is $17.07. The company’s market cap is $230.3 million.

Genocea Biosciences (NASDAQ:GNCA) last released its earnings data on Wednesday, August 6th. The company reported ($0.41) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.42) by $0.01. On average, analysts predict that Genocea Biosciences will post $-2.10 earnings per share for the current fiscal year.

Genocea Biosciences, Inc is a United States-based clinical-stage company that develops T cell vaccines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.